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Abstract 
To develop transgenic lines for conditional expression of desired genes in rats, we generated 
several lines of the transgenic rats carrying the tetracycline-controlled transactivator (tTA) 
gene. Using a vigorous, ubiquitous promoter to drive the tTA transgene, we obtained 
widespread expression of tTA in various tissues. Expression of tTA was sufficient to strongly 
activate its reporter gene, but was below the toxicity threshold. We examined the dynamics 
of Doxycycline (Dox)-regulated gene expression in transgenic rats. In the two transmittable 
lines, tTA-mediated activation of the reporter gene was fully subject to regulation by Dox. 
Dox dose-dependently suppressed tTA-activated gene expression. The washout time for the 
effects of Dox was dose-dependent. We tested a complex regime of Dox administration to 
determine the optimal effectiveness and washout duration. Dox was administered at a high 
dose (500 μg/ml in drinking water) for two days to reach the effective concentration, and 
then was given at a low dose (20 μg/ml) to maintain effectiveness. This regimen of Dox ad-
ministration can achieve a quick switch between ON and OFF statuses of tTA-activated gene 
expression. In addition, administration of Dox to pregnant rats fully suppressed postnatal 
tTA-activated gene expression in their offspring. Sufficient levels of Dox are present in 
mother’s milk to produce maximal efficacy in nursing neonates. Administration of Dox to 
pregnant or nursing rats can provide a continual suppression of tTA-dependent gene ex-
pression during embryonic and postnatal development. The tTA transgenic rat allows for 
inducible and reversible gene expression in the rat; this important tool will be valuable in the 
development of genetic rat models of human diseases. 
Key words: Rats; transgenic; tetracycline-controlled transactivator; tTA; Doxycycline; Leucine Rich 
Repeat Kinase 2; LRRK2 
1. Introduction 
Rodents are an ideal laboratory animal model for 
functional genetic studies, because breeding cycles are 
short and because methods of gene manipulation 
have been developed in laboratory mice and rats [1-5]. 
Compared to mice, rats have a longer history of use in 
physiological and pharmacologic studies [6, 7]. 
Therefore, a wealth of experimental data on rats can 
be supplemented with genetic analysis [1]. Rats show 
advantage over mice in the ease of microsurgery [8, 9], 
in multiple sampling, and in behavior analyses. Ad-Int. J. Biol. Sci. 2009, 5 
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ditionally, the rats are more affordable for breeding 
than larger mammalian animals [1, 6, 7]. However, 
mice have been preferred by geneticists for decades 
because totipotent embryonic stem (ES) cells have 
been initially developed in mice rather than in other 
mammalian animals [10]. The situation is going to 
change as totipotent ES cells are developed in rats [11, 
12]. Moreover, a need for transgenic rats has been 
pursued because rats often serve as a superior model 
of human disease, compared to mice [1, 2, 6, 7, 13]. 
Rats often recapitulate human disease pheno-
types more accurately than the mice, as exemplified 
by rats transgenic for the rennin-2 gene, the choles-
terylester transfer gene, or the huntingtin gene [14-16]. 
Rats model type 1 diabetes better than mice in both 
the pathogenesis of disease and the response to 
treatment. As suggested by epidemiological studies, 
type 1 diabetes is caused by non-genetic environ-
mental factors that operate in a genetically susceptible 
host to initiate a destructive immune process. A viral 
infection readily induces diabetes in several rat mod-
els [17], but fails to induce diabetes in mice [18]. 
Clinical studies suggest that neither parenteral nor 
oral insulin can prevent or delay diabetes onset in 
human patients [19]. Both parenteral and oral ad-
ministration of insulin prevents diabetes in mouse 
models [20], but fail to do so in rats. Data from the rat 
model, but not the mouse model, of diabetes is con-
sistent with clinical studies. Such differences may be 
caused by species-specific factors, a hypothesis that is 
supported by analysis of the rat genome [21]. The rat 
genome conserves genes that are involved in immu-
nity, metabolic detoxification, reproduction, 
chemo-sensation, and human diseases [22, 23]. In-
creasing evidence indicates that rats recapitulate hu-
man diseases more accurately than mice. To increase 
the diversity of animal models for human diseases, it 
is compelling to expand the availability of genetically 
manipulated rats. 
To model human diseases in animals, inducible 
mutations or overexpression of desired genes is nec-
essary when the genetic manipulation causes em-
bryonic or early postnatal lethality [24, 25]. As such, 
multiple systems have been developed for conditional 
gene manipulations. The Tet-off system has readily 
been used in transgenic mice [26-29]. Compared to 
thousands of transgenic mice reported, the availabil-
ity of transgenic rats is limited to about 100 transgenic 
lines characterized [1, 30-32]. As transgenic technol-
ogy advances in rats [1, 2], the number of transgenic 
rats is increasing at an accelerated speed [1, 33, 34]. To 
express genes of interest in a conditional pattern in 
rats, we developed transgenic rats carrying and ex-
pressing tetracycline-controlled transactivator (tTA) 
under the control of a ubiquitous promoter. The tTA 
transgenic rats expressed the transgene tTA in many 
tissues. The expression levels of the tTA transgene 
were sufficient to vigorously and reversibly activate 
reporter gene under control of the Tet-responsive 
promoter. These tTA transgenic rat lines will be useful 
in the conditional expression of human disease genes 
in the rats. 
2. Materials and Methods 
Construction of transgenic DNA and creation of 
transgenic rats 
A Tet-off system was chosen to produce induc-
ible and reversible gene expression in transgenic rats. 
This system is readily used in transgenic mice [26-29]. 
The Tet-off system is comprised of two elements: a 
tetracycline-controlled transactivator (tTA) and a 
tTA-dependent promoter. The tTA-dependent pro-
moter is a hybrid promoter that is constructed by 
juxtaposing multiple tetracycline-responsive elements 
(TRE) upstream of a minimal cytomegalovirus pro-
moter (TREminiCMV). When a gene is placed under 
control of the TREminiCMV promoter, transcription 
of the gene depends on activation by the transcrip-
tional activator tTA. The tTA activates its reporter 
gene in the absence of tetracycline or tetracycline de-
rivatives such as Dox (Dox), but is inactivated in the 
presence of Dox. For robust gene expression, a strong 
hybrid promoter, CAG (cytomegalovirus enhancer 
fused to chicken beta actin promoter), was used to 
drive a tTA gene that was extracted from the vector 
pTet-off (Clontech) [35, 36]. The transgenic construct 
CAG-tTA consisted of the CAG promoter, the non-
coding exon along with the first intron of the beta 
actin gene, tTA cDNA, and three repeats of the SV40 
polyadenylation signal (Figure 1A). The human Leu-
cine Rich Repeat Kinase 2 (LRRK2) gene tagged with 
hemaglutinin (HA) was driven by the TRE promoter 
and used as the reporter gene for tTA (Figure 2A). 
Both the CAGtTA and the TREhLRRK2-HA 
transgenic constructs were linearized by restriction 
digestion and purified from an agarose gel. The 
transgene DNA was injected into the pronucleus of 
fertilized single-cell embryos of Sprague-Dawley (SD) 
rats. Surviving eggs were transferred into pseudo-
pregnant female rats. Transgenic founder rats were 
identified by PCR-magnifying part of the transgenes 
with the following primers: 
5’-AGCCTCTGCTAACCATGTTC-3’ (forward) and 
5’-AACCTTCGATTCCGACCTCA-3’ (reverse) for the 
tTA transgene, and 
5’-CTGTTGATCGTCTTGGACTC-3’ (forward) and 
5’-CCCAATCATTTCCAACATCC-3’ (reverse) for the Int. J. Biol. Sci. 2009, 5 
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report gene hLRRK2. Copy number of the transgenes 
was determined by quantitative PCR. Transgenes 
were maintained on the genomic background of SD 
rats. Each line of the tTA transgenic founders was 
crossed with an expressing line of the hLRRK2-HA 
transgenic rats to produce double transgenic offspring 
(F1), in which the transcriptional activity of tTA was 
examined. Animal use followed NIH guidelines. The 
animal use protocol was approved by the Institutional 
Animal Care and Use Committees (IACUC) at Tho-
mas Jefferson University. 
Doxycycline treatment 
To suppress tTA-activated gene expression, 
doxycycline hydrochloride (Dox; a Sigma-Aldrich) 
was continually supplied in drinking water at desired 
concentrations. Dox-containing water was supplied in 
a light-protected bottle and was renewed every three 
days. Rats were given regular food and water sup-
plied with or without Dox of the indicated concentra-
tions. 
Quantitative PCR 
Copy number of the transgene was estimated by 
quantitative PCR. Genomic DNA was extracted from 
tail biopsy and was adjusted to a constant concentra-
tion of 100 ng/μl. A pair of primers was selected spe-
cifically for the tTA transgene: 
5’-AGCCTCTGCTAACCATGTTC-3’ (forward) and 
5’-AACCTTCGATTCCGACCTCA-3’ (reverse). In 
parallel, the rat tyrosine hydroxylase (TH; a known 
single-copy gene) gene was used as an internal control 
for PCR quantification and was magnified with the 
primers 5’-CTCAAGAATCCTGTCACCAG-3’ (for-
ward) and 5’-ACTGCCTTTCAGGGTATGTC-3’ (re-
verse). Rat genomic DNA was estimated to contain 3 x 
109 base-pairs. The tTA transgene DNA was dissolved 
in genomic DNA of nontransgenic rats to obtain a 
series of standards from one to ten copies per genome. 
The resulting standard curve of tTA gene copy num-
ber was used for estimation of tTA transgene copy 
number in individual transgenic lines. 
The mRNA level of the reporter gene human 
LRRK2 was also estimated with quantitative PCR. 
Total RNA was isolated from rat tissue with Trizol 
reagent (Sigma) and was further purified by digesting 
genomic DNA on a column (RNA easy kit and 
RNase-free DNase: Qiagen). One microgram of the 
purified RNA from each sample was reversely tran-
scribed to cDNA with oligo-dT primer (RT kit, Invi-
trogen). Relative levels of hLRRK2 mRNA in indi-
vidual samples were estimated by quantitative PCR 
with the following gene-specific primers: 
5’-CAGCCTGACTATCAACTTCT-3’ (forward) and 
5’-TTGTTTGTGGATCGCTGTGA-3’ (reverse) for the 
reporter gene hLRRK2, and 
5’-TGGTTCGCTACTCCCTTGAC-3’ (forward) and 
5’-CTTGATGGCCTGGGCAGTT-3’ (reverse) for rat 
L17 gene. The mRNA level of the L17 gene was used 
as an internal control for PCR quantification. 
For quantitative PCR, the gene-specific primers 
were used at a concentration of 500 nM. Gene doses 
were measured by quantitative PCR with SYBR green 
kit per manufacturer’s instruction (Qiagen). Cycling 
conditions were 15 min at 95°C followed by 40 cycles 
of 15 seconds at 94°C, 30 seconds at 60°C, and 20 
seconds at 72°C. Aliquots of the amplified products 
were separated on 3% agarose gels to ensure amplifi-
cation of the specific products at the predicted length. 
The threshold cycle number (Ct) for an examined 
gene was normalized to the Ct for the individual in-
ternal genes: TH gene for estimation of tTA transgene 
copy and L17 gene for estimation of reporter gene 
mRNA. The relative mRNA level of the reporter gene 
hLRRK2 was determined and expressed as a ratio of 
the mRNA level in the Dox-treated rats to that in the 
Dox-untreated rats, as described previously [37]. 
Western blotting 
Animal tissues were homogenized in phosphate 
buffer (pH 7.4) supplied with protease inhibitors 
(Sigma). Tissue debris, unbroken cells, and cell nuclei 
were removed by centrifugation at 16,000 × g for 10 
minutes. Protein content in the cleared lysate was 
determined by BCA assay (BioRad). Since protein 
product of the reporter gene human LRRK2 was 
about 280 kDa, the LRRK2 protein was barely de-
tected in completely denatured sample [38]. Protein 
sample of certain amounts was mixed with 2% 
SDS-containing loading dye and was partially dena-
tured by incubating at 60°C for 5 minutes. Proteins 
were separated on 4-20% gradient SDS-PAGE and 
blotted onto GeneScreen Plus membrane (Perkin 
Elmer). Immunoreactivity to the epitope HA was de-
tected by incubating the membrane with rabbit poly-
clonal antibody to HA (Rockland Inc., Pennsylvania). 
Immunoreactivity to GAPDH was also detected by 
incubating the membrane with a mouse monoclonal 
antibody to GAPDH (Abcam) and used as a control 
for equal loading. The immunoreactivity signal was 
developed with Super Signal kit (Pierce). 
Immunohistochemistry 
Rats were transcardially perfused with 4% para-
formaldehyde in 0.1 M ice-cooled phosphate buffer. 
Their brains were dissected and further fixed in the 
same fixative for additional 24 hours. The dissected 
tissues were dehydrated in 30% sucrose and cut into 
serial coronal sections (30 μm thick) on a Cryostat. For 
detection of human LRRK2 protein, brain sections Int. J. Biol. Sci. 2009, 5 
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were incubated sequentially with a rabbit polyclonal 
antibody to the epitope HA (1:200; Rockland), with 
biotinylated goat anti-rabbit IgG (1:500; Vector Labo-
ratories), and with peroxidase-conjugated 
avidin-biotin complex (ABC kit; Vector Laboratories). 
After thorough washing, bound antibodies were 
visualized by addition of diaminobenzidine (Vector 
Laboratories). Immunostained cells were observed 
under a Nikon microscope and were documented 
with a Nikon digital camera. 
Rotarod test 
Rats were first trained to stay on the rod of a ro-
tarod (Med Associates) at a constant speed of 5 rpm, 
once a day for 5 days. Following the training, rats 
were tested on the Rotarod with an accelerating speed 
of 0.2 rpm/s, starting at 5 rpm. During a testing day, 
each rat was given three successive trials with a 
20-minute interval. The latency to fall from the rod 
was recorded for each trial. The average latency was 
calculated for each testing day. 
Statistical analysis 
Data are expressed as means + SD. The statistical 
significance was tested with analysis of variance 
(ANOVA) followed by Tukey’s post hoc test to com-
pare group means. In all analyses, the null hypothesis 
was rejected at a level of 0.05. 
3. Results 
Copy-related expression of the tTA transgene in 
CAG-tTA transgenic rats 
Production of transgenic rats appears more dif-
ficult than creation of transgenic mice because the 
pronuclei of rat zygotes are less regular and less uni-
form than those of mouse zygotes. Furthermore, the 
plasma and pronuclear membranes of rat zygotes are 
more plastic and sticky than those of mouse zygotes. 
About 31–75% of rat zygotes are viable after microin-
jection and are ready for implantation into pseudo-
pregnant females [2, 30]. We injected 540 single-cell 
embryos of SD rats with the CAGtTA transgene DNA 
at a concentration of 2ng/µl (microinjection buffer: 
Invitrogen) and transplanted 386 viable embryos into 
12 pseudopregnant SD female rats (Figure 1A). From 
68 pups, we identified three founder rats carrying the 
CAGtTA transgene (Figure 1B). Two of the three 
transgenic founders transmitted the transgene (Figure 
1B: lines 5 and 11); however, founder 4 was infertile. 
We determined the copy number of the transgene in 
individual lines by quantitative PCR and detected 2 
copies of the CAGtTA transgene in the line 5, 8 copies 
in the line 11, and 25 copies in the founder 4. The 
transgene was integrated at a single location in the 
genomes of the lines 5 and 11 because the copy num-
ber of the CAGtTA transgene was constant across 
generations. In addition, we tried to breed tTA trans-
genic lines to obtain homozygotes and succeeded 
with line 5 but not with line 11 (0 homozygotes in 30 
transgenic offspring). No difference was observed in 
gross health between the homozygote and the he-
mizygote tTA rats.  
 
 
Figure 1. Widespread expression of the tTA 
transgene in tTA transgenic rats. A, Schematic shows 
the structure of the tTA transgene. Two pairs of primers 
were designed for regular PCR to determine the genotypes 
of transgenic rats (P2 + P3) or for reverse-transcriptional 
PCR (RT-PCR) to detect expression of the transgene tTA 
(P1 + P3). B , Results of representative PCR with the 
primers P2 and P3 show three founder rats (lines 4, 5, and 
11). C+, nontransgenic rat DNA mixed with the transgene 
tTA; C-, nontransgenic rat DNA. C, RT-PCR with primers 
P1 and P3 detected a wide expression of the transgene tTA 
in various tissues: OB, olfactory bulb; hippo, hippocampus; 
CB, cerebellum; BS, brainstem; SC, spinal cord; SM, skeletal 
muscle; and other tissues as indicated. RT-PCR for the rat 
L17 gene serves as an internal control for equal loading of 
cDNA pools. RT-PCR was run for 25 cycles to show the 
difference in transgene expression between the two ex-
pressing lines. D, Western blotting showed that expression Int. J. Biol. Sci. 2009, 5 
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of the tTA transgene was not detected at protein level in 
the two transmittable lines. C+, HEK293 cells were tran-
siently transfected with the tTA transgene construct and 
the cell lysate was used as the positive control. 
 
To detect transgene expression, we first tried 
immunoblotting with commercially available anti-
bodies that were raised with peptides corresponding 
to the tTA protein. Unfortunately, we could not detect 
tTA protein by western blotting in the two transmit-
table lines (Figure 1). In previous studies, low expres-
sion of tTA transgene has been shown sufficient to 
vigorously activate a tTA-dependent reporter gene 
[26, 39]. We designed a pair of primers spanning the 
intron of tTA transgene, and thus, we could identify 
mature tTA mRNA by RT-PCR (Figure 1A). We de-
tected expression of the tTA transgene in various tis-
sues of the two transmittable lines (Figure 1C). In 
many tissues, the tTA transgene was expressed at 
higher levels in the 8-copy line (line-11) than in the 
2-copy line (line-5), suggesting a pattern of transgene 
copy-related expression. 
Vigorous activation of tTA-dependent reporter 
gene in the double transgenic rats  
To test whether limited levels of tTA gene ex-
pression were sufficient to activate its target genes in 
vivo, we crossed the tTA transgenic lines with a 
tTA-responsive reporter line that carried human 
LRRK2 gene under control of the TREminiCMV 
promoter (Figure 2A). By RT-PCR, we detected a 
widespread expression of the reporter gene in many 
tissues examined (Figure 2B). Since the reporter gene 
was tagged by hemaglutinin (HA), expression of the 
reporter gene could be detected by immunoblotting or 
immunohistochemistry for HA antigen. HA immu-
noreactivity was detected only when both the tTA and 
the reporter genes were presented in the transgenic 
rats, but was not detected when only the reporter 
transgene was present (Figure 2C). These results in-
dicate that expression of the reporter gene depended 
on tTA activation and that leakage of the reporter 
gene was negligible. Further, western blotting de-
tected strong HA immunoreactivity in the double 
transgenic rats carrying the 8-copy tTA transgene, but 
detected relatively weak HA immunoreactivity in the 
rats carrying 2-copy tTA transgene (Figure 2C). Ex-
pression levels of the reporter gene corresponded 
with those of the tTA transgene. In addition, immu-
nohistochemistry with an HA antibody detected 
widespread expression of the reporter gene in many 
tissues of double-transgenic animals, but no expres-
sion in tissues of animals carrying the reporter trans-
gene alone (Figure 2D-G). Consistent with the previ-
ous findings in transgenic mice [26, 39], our results 
suggest that limited levels of tTA transgene expres-
sion were sufficient to vigorously activate its reporter 
gene in vivo. 
 
 
Figure 2. A reporter gene driven by a 
tTA-dependent promoter is transcriptionally acti-
vated by tTA and robustly expressed in various 
tissues. A, Schematic shows the structure of the reporter 
gene for probing tTA transcriptional activity. The human 
LRRK2 gene (hLRRK2), tagged by hemaglutinin (HA), was 
driven by a hybrid promoter comprising a minimal CMV 
promoter of 110 bp and seven repeats of tetracy-
cline-responsive elements. The noncoding exon 1 and the 
first intron of human ubiquitin C gene were placed between 
the hybrid promoter and the human LRRK2 gene to en-
hance gene expression. A pair of primers (P1, P2) was 
designed to magnify the mature cDNA of the transgene, 
giving a band of 240 base-pairs. B, Representative RT-PCR 
shows that the reporter gene was widely expressed in 
various tissues of a double transgenic rat carrying both the Int. J. Biol. Sci. 2009, 5 
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CAGtTA and the TREhLRRK2 transgenes. Genomic 
DNA-eliminated cDNA pools were extracted from the 
following tissues: 1, olfactory bulb; 2, cortex; 3, striatum; 4, 
hippocampus; 5, cerebellum; 6, brainstem; 7, spinal cord; 8, 
skeletal muscle; 9, heart; 10, lung; 11, liver; 12, spleen; 13, 
kidney; 14, stomach; 15, intestine; 16, colon; 17, testis; 18, 
ovary; 19, skin. RT-PCR for rat L17 gene serves as an in-
ternal control for equal loading of cDNA pools. C, Western 
blot detected widespread expression of the reporter gene 
hLRRK2 upon activation by the tTA transgene in transgenic 
lines 5 or 11. D-G, Immunoreactivity to HA tag is detected 
only in the tissues of the CAGtTA/TREhLRRK2-HA double 
transgenic rat (E, G), not in the tissues (D, F) of non-
transgenic rats (WT). 
 
Suppression of tTA-activated gene expression by 
Dox 
One advantage of the tetracycline-regulatory 
system is that transgene expression can be suppressed 
temporally. To test whether the tTA-activated gene 
was responsive to Dox, we first treated adult rats 
carrying both the tTA and the reporter transgenes. 
When administered at a constant concentration in 
drinking water, Dox effectively suppressed expres-
sion of the tTA-dependent reporter gene and reached 
its maximal effect in a dose-dependent pattern (Figure 
3A, B). By day 5, Dox administered at 500 μg/ml re-
duced mRNA and protein levels of the reporter gene 
below detection threshold. In contrast, lower doses of 
Dox took a longer time to reach its maximal effects: 
100 μg/ml and 20 μg/ml of Dox reached the maximal 
effect by day 7 and by day 10, respectively. To im-
prove drug efficiency, we tested a complex regime of 
Dox administration: Dox administered at 500 μg/ml 
for 2 days and then at 20 μg/ml for the remainder of 
the experiment. The complex (Cp) regime reached 
maximal effect by day 5 and achieved a comparable 
result to the highest dosage for Dox (Figure 3A, B).  
To study the functions of embryo-lethal genes in 
adult animals, we should avoid expression of genes at 
the embryonic and postnatal stages. Therefore, we 
tested the gene-suppression efficiency of 
milk-secreted Dox in postnatal rats. Expression of the 
reporter gene was effectively suppressed in postnatal 
rats from 2 days of age through weaning when their 
mother was given Dox (20 μg/ml) in drinking water 
since the date of mating (Figure 3C, D). Our results 
show that expression of the tTA-dependent transgene 
was subject to a tight and constant suppression by 
Dox in both adult and postnatal rats. 
 
 
Figure 3. Dox-dependent suppression of tTA-activated gene expression in transgenic rats. A, Dox turned off a 
tTA-dependent report gene at a dose-dependent speed. Adult female rats doubly transgenic for CAGtTA (line 11) and 
TREhLRRK2 were given Dox in drinking water at the indicated concentrations (Cp: 500 μg/ml for 2 days and then 20 μg/ml 
for the duration of the experiment). At the indicated time (d: day) after Dox treatment, rats were sacrificed for tissue 
collection. The mRNA levels of the report gene were measured by quantitative RT-PCR and expressed as a percentage of 
levels in the Dox-untreated rats. Data are means + SD (n = 3). B, Consistent with the RT-PCR results shown in A, western 
blot detected no expression of the reporter gene in the forebrain after Dox was administered for certain time (d: day). Brain Int. J. Biol. Sci. 2009, 5 
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tissues were taken from the same rats used for the RT-PCR shown in A. Immunoreactivity to GAPDH was also measured 
as a control for equal loading. C, Milk-secreted Dox continually suppressed tTA-dependent gene expression in neonatal rats. 
Pregnant rats were given Dox (20 μg/ml) in drinking water from the time of mating onward. The pups were sacrificed at 
indicated ages (d: day). Their forebrain was removed from the skull and dissected for extraction of RNA and protein. The 
mRNA levels of the reporter gene were measured by quantitative RT-PCR and expressed as a percentage of levels in the 
Dox-untreated rats. Data are means + SD (n = 4). Protein levels of the reporter gene were measured by western blot (D). 
For detection of HA-tagged human LRRK2 protein, 50 µg of total protein from each sample was loaded. 
 
Reversibility of tTA-dependent gene expression 
after Dox withdrawal 
Compared to other gene regulatory systems, 
such as the Cre-lox system, a big advantage of the Tet 
regulatory system is that gene suppression can be 
released by Dox withdrawal. We first tested gene 
restoration in adult rats that were treated with Dox for 
20 days. Expression of the reporter gene was effi-
ciently restored in all the rats treated with three re-
gimes of Dox (Figure 4A, B). Sixty days were required 
to remove the remnant effect of Dox administered at 
500 μg/ml, but only 40 days were required to elimi-
nate the remnant effect of Dox administered at 20 
μg/ml (Figure 4A, B). Restoration time of gene ex-
pression is inversely relative to the dosage of Dox 
administered. We then tested recovery of gene ex-
pression in the rats inherently treated with Dox. We 
o b s e r v e d  t h a t  g e n e  r e c o v e r y  t i m e  d e p e n d e d  o n  t h e  
age at Dox withdrawal. Periods of 40, 60, and 90 days 
were needed to recover gene expression in the rats 
depleted of Dox at ages of 15, 30, and 60 days, respec-
tively (Figure 4C, D). Rats grow faster at early ages 
than at later ages (Figure 5A). Early withdrawal of 
Dox may require less time to remove the remnant 
effect of Dox due to a dilution effect from physical 
body expansion. 
 
 
Figure 4. Restoration of tTA-dependent gene expression depends on the dosage of Dox administered. A, B: 
Residual effect of Dox temporally administered depends on the dose of Dox. Female rats at age 40 days were given Dox in 
drinking water at indicated concentrations (Cp: 500 μg/ml for 2 days and then 20 μg/ml for the rest time) for 20 consecutive 
days. Rats were sacrificed at indicated days (d: day) after Dox withdrawal. Restoration of gene expression in the forebrain 
was examined by quantitative RT-PCR for human LRRK2 mRNA (A) and by western blotting for HA immunoreactivity (B). 
C, D: Residual effects of Dox depend on the duration of Dox administration. Mating rats were given Dox in drinking water 
at 20 μg/ml. Dox was withdrawn (WD: withdrawal) at the indicated ages of newborn rats. Forebrains of neonates were 
dissected at the indicated times after Dox withdrawal. Expression of the reporter gene was examined by quantitative 
RT-PCR for human LRRK2 mRNA (C) and by western blotting for HA immunoreactivity (D). Immunoreactivity to GAPDH 
served as a control for equal loading (50 μg of total protein per lane). Data are means + SD (n = 3-4). 
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Figure 5. The tTA transgene does not affect rat 
growth or psychomotor function. A, The body weight 
of each rat was measured weekly after genotypes were 
determined.  B, Psychomotor function of male rats was 
tested with a Rotarod weekly after a 5-day training period. 
Performance on the Rotarod was not different between the 
tTA transgenic rats and their nontransgenic littermates. 
Data are means + SD (n = 5-8). 
 
No effect of the tTA transgene on animal growth 
or motor function 
In transgenic studies, gene insertion may cause 
unwanted phenotypes due to interruption of other 
genes at the insertion site. In addition, overexpression 
of the transcriptional factor tTA may cause side effects 
[39]. We examined tTA transgenic rats for overall 
health, but failed to observe any abnormal pheno-
types. No differences were observed in the size of 
liver, heart, kidney, and brain between the tTA 
transgenic and the nontransgenic rats (data not 
shown). Compared to nontransgenic littermates, the 
tTA transgenic rats gained body weight at comparable 
speeds during postnatal development (Figure 5A). We 
monitored motor function using Rotarod test and 
observed no difference in psychomotor function be-
tween tTA transgenic and nontransgenic littermates 
(Figure 5B). Insertion and expression of the tTA 
transgene did not affect the growth or psychomotor 
function of rats. 
4. Discussion 
To develop a transgenic line for conditional ex-
pression of desired genes in rats, we used the tetracy-
cline regulatory system and generated several lines of 
the transgenic rats carrying the tTA transgene. Using 
a vigorous and ubiquitous promoter to drive the tTA 
transgene, we obtained widespread expression of tTA 
in the central nerve system, skeletal muscle, heart, 
lung, and in most abdominal organs. Expression of 
the tTA was sufficient to vigorously activate its re-
porter gene, but was below the threshold to produce 
toxicity to the rats. These tTA transgenic rats are a 
model of inducible and reversible gene expression in 
the rat, and could be valuable to the development of 
genetic rat models for human diseases. 
The Tet-regulatory system is widely used to 
achieve inducible and reversible expression of desired 
genes in vivo. To date, a great number of transgenic 
mice have been generated to express tTA (Tet-off) or 
rtTA (Tet-on) transactivators in ubiquitous or tis-
sue-specific patterns [26, 27, 39]. While few lines of 
transgenic rats have been created to express tTA in 
cell-specific patterns [29, 40, 41], a single line of tTA or 
rtTA transgenic rat is not available for ubiquitous 
activation of reporter gene in various cell types. To 
obtain ubiquitous expression of the tTA transgene in 
rats, we chose the ubiquitous promoter CAG, a hybrid 
promoter that has been constructed by fusing the cy-
tomegalovirus enhancer with the chicken beta actin 
promoter. CAG has been shown to produce ubiqui-
tous and robust gene expression in transgenic mice 
[35, 42, 43]. Although CAG is a vigorous promoter, 
expression of tTA protein was not detectable by im-
munoblotting in the two transmittable lines (data not 
shown). We used the original bacterial codon for tTA. 
Sanbe et al. reported that bacterial codon usage bias 
leads to alternative splicing of tTA mRNA and results 
in a low abundance of full-length tTA mRNA [39]. As 
a transcriptional activator, tTA at limited levels 
should be sufficient to activate its target gene. Exces-
sive expression of tTA protein may cause toxicity to 
the cells because high abundance of exogenous 
transactivator may interfere with cellular transcrip-
tion activity.  
Indeed, enhanced expression of tTA using 
mammalian codon causes toxicity in transgenic mice 
[39, 44]. To balance ubiquitous with adequate gene 
expression, we chose a ubiquitous promoter as the 
driver, but used the original bacterial codon for tTA. 
Consistent with previous finding in transgenic mice Int. J. Biol. Sci. 2009, 5 
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[26, 35, 39, 42, 43], our results in transgenic rats dem-
onstrated that expression of tTA with bacterial codon 
was under the detection threshold by western blot-
ting, but was sufficient to vigorously activate its target 
gene in various tissues. Insertion or expression of the 
tTA transgene may interfere with endogenous genes 
and cause toxicity to the animals. If the toxicity of the 
tTA transgene is evident, the toxicity should be re-
flected as an effect on growth, overall health, or organ 
development. In the two transmittable lines of trans-
genic tTA rats, no detectable abnormality was ob-
served. These results suggest that insertion of the tTA 
transgene did not result in a deleterious dominant 
mutation and that expression of the tTA transgene did 
not obviously interfere with endogenous genes. These 
transgenic rats express tTA within a safe dosage and 
at sufficient levels to activate the target gene. 
The dynamics of Dox-regulated gene expression 
were thoroughly examined for the first time in trans-
genic rats. We not only examined suppression of 
tTA-activated gene expression by Dox, but also ex-
amined reversibility of tTA-dependent gene expres-
sion after Dox withdrawal. Both the suppression and 
the reversal of gene expression were tested in adult 
and neonatal rats. In the two transmittable lines, 
tTA-mediated activation of the reporter gene was 
fully subjected to the regulation by Dox. In transgenic 
mice, Dox dose-dependently suppresses 
tTA-activated gene expression and washout of Dox 
remnant effect also corresponds to Dox dosage used 
[26, 39]. Similarly, Dox reached its maximal effect of 
gene suppression at speeds proportional to its dose. 
High dose of Dox (500 μg/ml in drinking water) took 
a short time to fully suppress tTA-activated gene ex-
pression, but required a much long time to remove its 
remnant effect. In our studies, a duration of 5 days 
appeared to be the minimal time for complete gene 
suppression by orally administered Dox. We tested a 
complex regime of Dox administration to quickly 
reach the maximal effect but to successfully avoid 
extended duration of Dox cleanout. Dox was used at a 
high dose (500 μg/ml in drinking water) for 2 days to 
reach its effective concentration quickly and then used 
at a low dose (20 μg/ml) to maintain its effect con-
stantly. This improved regime of Dox administration 
can help achieve a quick switch of tTA-activated gene 
expression between ON and OFF status. In addition, 
parental administration of Dox fully suppressed 
tTA-activated gene expression in offspring rats. 
Milk-secreted Dox was sufficient to reach its effective 
concentration in neonatal rats. Parental administra-
tion of Dox can help provide a constant suppression 
of tTA-dependent gene expression during embryonic 
and postnatal development. We also tested the tTA 
transgenic lines with another reporter gene and ob-
served similar results (data not shown). 
Although laboratory mice are preferred for func-
tional genetics, laboratory rats show significant ad-
vantages as model animals in pharmacological and 
toxicological studies, in behavioral analysis, in mi-
crosurgery such as cell transplantation, and in studies 
on neurological diseases. In modeling some human 
diseases, animal species may play an important role in 
phenotypic expression. For example, no substantial 
loss of dopaminergic neurons is observed in human 
alpha-synuclein transgenic mice [45, 46], but progres-
sive loss of the neurons is induced by transient ex-
pression of human alpha-synuclein in rats [47]. Ani-
mal species may not be a sole factor contributing to 
the variation of phenotypic expression in al-
pha-synuclein models. In some genetic models for 
human disease, developmental compensation may 
dilute phenotypic expression when the gene is con-
stitutively mutated. Such compensatory changes are 
increasingly observed in genetic models [48, 49]. 
Disrupting one gene of the JNK family causes com-
pensatory changes in the other related genes [49]. 
Studies on Jnk2 knockout mice with the gene dis-
rupted from germline suggest a negative regulatory 
role in cell proliferation for the protein kinase Jnk2 
[50]. In contrast, studies of Jnk2 inhibition in adult 
mice suggest Jnk2 as a positive regulator for cell pro-
liferation [49]. These distinct phenotypes may result 
from developmental compensation by upregulated 
expression of the related genes [49]. Compared with 
the human, the rodent has a short lifetime. Develop-
mental compensation may buffer the detrimental ef-
fects of gene mutation and thus attenuate or even 
prevent the phenotypes of gene mutation from de-
veloping in a rodent’s lifetime. Selective expression of 
disease genes in adult animal may increase the chance 
to reproduce the phenotypes of human diseases in the 
animals. Recent advances in transgenic RNAi indi-
cates that RNAi-mediated gene silencing can repro-
duce phenotypes of the gene knockout [37, 51, 52]. 
Transgenic RNAi is a convenient approach to achieve 
hypomorphic phenotypes in the transgenic rats. To 
maintain RNAi transgenic lines, conditional expres-
sion of the RNAi transgene is necessary when the 
hypomorphic phenotype is lethal or infertile. In the 
aforementioned applications, the tTA transgenic rats 
would be a valuable tool for accomplishment of these 
goals. 
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